TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01570582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin and paclitaxel
Description: Subjects assigned to Arm I Neople taksoljuwa Latin week the first day of the week based outpatient / inpatient treatment receive it. The subjects first received taksoljureul given over 3 hours followed by 30 minutes will be administered Neople Latin week.
Study: NCT02294019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg caplet
Description: 400 milligram (mg) caplet according to Drug Facts label
Study: NCT04697147

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conscious Discipline-Based Environmental Enrichment Intervention
Description: Conscious Discipline, a social-emotional skills-based learning program that draws on current brain research and fosters enhanced connections between parents and their children.
Study: NCT01275248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Oral tablets in 0.5mg or 0.75mg strength

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Oral tablets in 0.5mg or 0.75mg strength

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet to match the experimental interventions
Study: NCT00855712

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Organ Care System
Description: The Organ Care System (OCS) is a portable organ perfusion and monitoring system intended to preserve a donated heart in a near normal physiologic beating state during transport for eventual transplantation into a recipient. The OCS maintains organ viability by providing a controlled environment that simulates near-normal physiological conditions, continuously perfusing the donated heart with warm, oxygenated blood, supplemented with the Solution Set. The blood is collected from the donor and continuously circulated to the organ in a closed circuit along with the Solution. The OCS preserves and monitors the organ's perfusion and metabolic state after explantation from a donor and connection to the device, during transportation to the recipient site, and until disconnection from the device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cold Cardioplegia Solution
Description: This is the standard of care solutions used to arrest and preserve the donated heart during transport until arrival at recipient hospital
Study: NCT02383329

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: The ONS provided to the children intervention group will be a ready to drink age adapted oral nutrition supplement providing 1,5 kcal/ml
Description: The ONS provided to the children intervention group will be a ready to drink age adapted oral nutrition supplement providing 1,5 kcal/ml
Study: NCT01975025

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Short daily dialysis for 2 weeks
Study: NCT02443844

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transurethral Resection
Description: Endoscopic treatment of bladder cancer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: Medical treatment for benign prostate hyperplasia
Study: NCT00360022

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Joint visits
Description: Both the pediatric GI specialist and the adult GI specialist will see the patient together at 2 different visits. The first joint visit is lead by the pediatric MD and the second joint visit is lead by the adult MD.
Study: NCT03876340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment algorithm
Description: Digital infrared thermograms will be obtained during the first contact with the patients. Temperature recordings of the injured and healthy skin will be used to calculate the temperature difference between the structures. The thermograms will be used to dictate the initial treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current treatment
Description: Digital infrared thermograms will be obtained during the first contact with the patients. Temperature recordings of the injured and healthy skin will be used to calculate the temperature difference between the structures, but the results will be kept sealed until the study is finished. The patients will receive the usual standard of care as dictated by the surgical team.
Study: NCT06013787

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nuestras Historias
Description: Nuestras Historias is a digital story curriculum that is displayed on a small solar-powered tablet. The curriculum is a collection of 7 digital stories used to discuss health issues during pregnancy that the community identified as important. The digital stories are short videos that combine local photos and local voices sharing real-life narratives about experiences during pregnancy. The videos were made in collaboration with community health workers and local mothers.
Study: NCT04110834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole gel once daily
Description: itraconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole gel twice daily
Description: itraconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the same procedure as before is used to prepare the nanoemulsion intermediate gel but the active ingredient, itraconazole, is not added then applied twice daily in the same manner
Study: NCT00353457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine, Oxaliplatin and Cetuximab
Description: Capecitabine 825mg/m2 po BID D1-15 of 21 x2 cycles (Cyle 1 and 2), Capecitabine 825mg/m2 po BID weekly Sun PM-Fri AM x2 cycles (cycle 3 and 4), Capecitabine 825mg/m2 po BID D1-15 of 21 x4 cycles (cycle 5,6,7,8) Oxaliplatin 130mg/m2 IV Day 1 every 3 weeks x2 cycles (Cycle 1 and 2), Oxaliplatin 50mg/m2 IV weekly every Monday x2 cycles (Cycle 3 and 4), Oxaliplatin 130mg/m2 IV day 1 every 3 weeks x4 cycles (Cycles 5,6,7,8) Cetuximab 400mg/m2 IV cycle 1 day1, Cetuximab 250mg/m2 Day 1,8,15 of 21 for cycles 1-8

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 45 Gy in 25 fractions, 3-fraction boost 5.4 Gy
Study: NCT00852696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: Solifenacin is used to treat overactive bladder. It works by relaxing the bladder muscles to prevent urgent, frequent, or uncontrolled urination. Take orally once daily for 9 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take orally once daily for 9 weeks.
Study: NCT03801707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir / Velpatasvir Oral Tablet [Epclusa]
Description: fixed dose combination medication once a day for 12 weeks for the treatment of hepatitis C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET]
Description: Three tablets once a day for 12 weeks for treatment of hepatitis C
Study: NCT02637141

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 714
Description: AMG 714 administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 714
Description: AMG 714 administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to AMG 714 administered by subcutaneous injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Gluten Challenge
Description: Gluten-free cookies (Finnish rusks)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Gluten Challenge
Description: Gluten-free cookies (Finnish rusks)
Study: NCT01509209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine / Levocetirizine
Description: tablet, BID everyday

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pseudoephedrine / Levocetirizine
Description: tablet, BID everyday
Study: NCT00290420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine profilaxis
Description: Prevention:~Give a profilaxis with chloroquine once a week to prevent Plasmodium vivax malaria attacks and to prevent harmfull effect on birth outcomes
Study: NCT00562107

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Symphony DR 2550 and REPLY DR cardiac pacemakers
Description: AAISafeR/SafeR ON

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Symphony DR 2550 and REPLY DR cardiac pacemakers
Description: DDD(R) (SafeR OFF)
Study: NCT01630811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nuedexta
Description: Nuedexta (Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg) will be given once daily for 7 days. If well-tolerated, it will be given every 12 hours for the next 7 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given once daily for 7 days.
Study: NCT01885234

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Pregnant women with Gestational Diabetes and pregnant women with chronic hypertension will perform 50 minutes of aerobic exercise in a bicycle, 3 times a week

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Stretch exercise
Description: Pregnant women with Gestational Diabetes and pregnant women with chronic hypertension will perform 50 minutes of stretch exercise, once a week
Study: NCT04256018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mogamulizumab
Description: Administered 1 mg/kg as an intravenous infusion over at least 60 minutes on Days 1, 8, 15, and 22 of the first 28 day cycle and on Days 1 and 15 of each subsequent cycle.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: LD TSEBT
Description: Patients will receive total skin dose of 12 Gy fractionated at 4 to 6 Gy per week, for 2-3 weeks
Study: NCT03750513

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy
Description: Given LET optimized IMPT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00607932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Description: 2, 4, 6 months post baseline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medical chart review
Description: 2,4,6 months post baseline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medical chart review
Description: 2,4,6 months post baseline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study: NCT02003209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibition Therapy
Description: Given at the investigator's discretion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cytology Specimen Collection Procedure
Description: Undergo 2 core biopsies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Undergo 2 core biopsies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Given SC

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Undergo lumpectomy or mastectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo lumpectomy or mastectomy

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole Breast Irradiation
Description: Undergo whole breast irradiation
Study: NCT00607932

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study: NCT04510571

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluating Postoperative Pain After Root Canal Treatment with Protaper Next
Description: Patients were randomly separated into two groups and root canal treatments were completed with Protaper Next file systems. Instrumentation time for each system was noted and patients were given a pain scale which included visual analog scale for 6, 24, 48 and 72 hours after treatment.Postoperative pain scores and instrumentation times were analyzed statistically with chi square test and student t test.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluating Postoperative Pain After Root Canal Treatment with Reciproc Blue Files
Description: Patients were randomly separated into two groups and root canal treatments were completed with Reciproc Blue file systems. Instrumentation time for each system was noted and patients were given a pain scale which included visual analog scale for 6, 24, 48 and 72 hours after treatment.Postoperative pain scores and instrumentation times were analyzed statistically with chi square test and student t test.
Study: NCT04309747

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nanosecond knife liver cancer ablation
Description: This trial is a prospective, multi-center, single-arm clinical trial. Four hospitals with national medical clinical trial institution qualifications are selected as clinical trial centers. Qualified participants will receive nanosecond pulse ablation therapy according to the routine procedures. The results will be recorded according to the requirements of the primary and secondary efficacy indicators. After then, statistical comparisons of effectiveness and safety of the product will be made according to groups.
Study: NCT02003209

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole Breast Irradiation
Description: Undergo whole breast irradiation
Study: NCT01266083

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Galinpepimut-S
Description: Galinpepimut-S admixed with the adjuvant Montanide following specified schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: subcutaneous injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Montanide
Description: adjuvant
Study: NCT02390635

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo 18F-FDG PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diffusion Weighted Imaging
Description: Undergo whole body PET/MRI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo 18F-FDG PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo whole body PET/MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo 18F-FDG PET/CT and whole body PET/MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Three-Dimensional Spoiled Gradient MRI
Description: Undergo whole body PET/MRI
Study: NCT03072849

Intervention type: PROCEDURE
Intervention: Pulmonary function testing
Description: Each enrolled patient will receive pulmonary function testing every three months. Pulmonary function testing includes spirometry, plethysmography, and diffusion capacity measurements.

Intervention type: DRUG
Intervention: FAM Therapy
Description: All patients who have evidence of early airflow obstruction on pulmonary function testing will be started on FAM therapy. Early airflow obstruction is defined by a FEV1 decline of ≥10% predicted in addition to a FVC \<0.8.
Study: NCT03495505

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WiSE-CRT
Description: Intervention will involve placement of the WISE-CRT system which consists of a transmitter, battery and electrode.
Study: NCT03425799

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9% Inj
Description: Inactive ingredient mixture for injection without drug, intravenous infusion bags containing normal saline, manufactured and provided by Exela Pharma Sciences, LLC from a single batch / lot.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic Acid Intravenous Infusion Bags (10 mg/mL), manufactured and provided by Exela Pharma Sciences, LLC from a single batch / lot.
Study: NCT03762252

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: A solid filiform needle will be inserted over active trigger points in the scalene muscles for 30 seconds. The aim will be to elicit local twitch responses or the referred pain pattern of the scalene muscles.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: The therapist will apply manual compression over active trigger points in the scalene muscles for 30 seconds
Study: NCT03378206

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hinged 8-figure plate
Description: Hinged 8-figure plate has two arms and a built-in hinge. The rotation of the two arms ranged from 155° to 170° to better fit the contour of the physis in all stages of angular correction. That automatic change can also disperse repeated stress on the surface of periosteum and perichondrium during walking.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional 8-figure plate
Description: Conventional 8-figure plate is a widespread device to treat angular deformity of lower limbs with moderate successful rate. The device was designed based on the principle of tension band model. It consists of a plate and two screws (epiphyseal screw and metaphyseal screw).
Study: NCT02202811

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Forced Desynchrony
Description: all sleep opportunities and other activities will be scheduled by the experimenter so that by the end of the study these activities are spread evenly across all phases of the internal body clock.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forced Desynchrony
Description: all sleep opportunities and other activities will be scheduled by the experimenter so that by the end of the study these activities are spread evenly across all phases of the internal body clock.
Study: NCT00942201

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Single loading dose in ED 0.6 mg/kg, rounded to nearest 2 mg,use 4 mg tabs max dose 16 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Firstdose in ED 0.6 mg/kg, rounded to nearest 2 mg, use 4 mg tabs max dose 16 mg; a prescription for second dose as above to be taken on day 3 after discharge
Study: NCT03192332

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stent-retriever thrombectomy with revascularization device of the Solitaire™ type
Description: Mechanical thrombectomy with a stent-retriever revascularization device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent-retriever thrombectomy with revascularization device of the Solitaire™ type
Description: Mechanical thrombectomy with a stent-retriever revascularization device

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous thrombolysis with recombinant tissue-type plasminogen activator (IV t-PA)
Description: Bridging thrombolysis (IV t-PA plus mechanical thrombectomy) according to current European and North American stroke guidelines.
Study: NCT01599351

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: The radiographic-fluoroscopic system
Description: Fluoroscopy was used during ERCP procedure. With automatic brightness adjustment, patients with thicker body will get greater radiation dose.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: The radiographic-fluoroscopic system
Description: Fluoroscopy was used during ERCP procedure. With automatic brightness adjustment, patients with thicker body will get greater radiation dose.
Study: NCT02976467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulacimstat (BAY1142524)
Description: 25 mg BAY 1142524 are given twice daily over a treatment period of 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets are given twice daily over a treatment period of 6 months
Study: NCT02857595

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Behavioral Weight Loss program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Behavioral Weight Loss program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Behavioral Weight Loss program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss Nomogram

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss Nomogram

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bite Counter
Study: NCT02637141

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gluten Challenge
Description: Gluten-free cookies (Finnish rusks)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten Challenge
Description: Gluten-containing cookies (Finnish rusks), 1-2 g gluten per serving

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten Challenge
Description: Gluten-containing cookies (Finnish rusks), 1-2 g gluten per serving

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gluten Challenge
Description: Gluten-containing cookies (Finnish rusks), 1-2 g gluten per serving
Study: NCT00857038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline tablets, 100mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets 100mg